The global burden of noncommunicable diseases (NCDs) is increasing and becoming a public health issue throughout the world [1]. Globally, diabetes caused 1.6 million deaths and 47% of all deaths before the age of 70 years in 2021. Diabetes increases the risk of death from kidney and cardiovascular diseases [2]. The prevalence of diabetes has been increasing over the last few decades in all countries and is considered a global epidemic [3], more quickly in low- and middle-income (LMICs) countries than in high-income countries. Moreover, diabetic treatment coverage was the lowest in the low- and middle-income range in 2022 [4]. It is alarming that an estimated half of the global people (49.7%) living with diabetes remain undiagnosed [5]. Diabetes has acute complications including ketoacidosis, hypoglycemia, or hyperglycemia. Chronic complications are macroangiopathy, retinopathy, nephropathy, neuropathy, and diabetic foot. Patients with diabetes are vulnerable to infections, myopathy, osteoporosis, arthropathies, and liver damage [6]. Patients with diabetes may be able to prevent or delay diabetic health problems by maintaining a healthy lifestyle, taking medicine regularly, and controlling blood glucose levels [7].

The use of telenursing is increasing significantly during and after the COVID-19 pandemic to treat and prevent chronic diseases [8]. As a field, it is part of telemedicine and has many points of contact with other medical and nonmedical applications, such as telediagnosis, teleconsultation, and telemonitoring. The field, however, is still being developed as the information on telenursing is not comprehensive enough [9].

Telenursing has been adopted by many developed and developing countries. It reduces health care costs and increases the coverage of health care to outreach, rural, small, or sporadically populated regions [10]. It is useful for the increasing number of aging and chronically ill populations [11]. Among its many benefits, telenursing may help solve increasing shortages of nurses [12]; to reduce distances and save travel time and keep patients out of hospital [10]. A greater degree of job satisfaction has been registered among telenurses [13]. Continuous glucose monitoring (CGM) in patients with diabetes by integrating diagnostic devices for 24-hour real-time data transmission [14] and IBM Watson Health for personalized lifestyle optimization can help to identify and prevent the early appearance of diseases. It allows rural patients to receive personalized, high-quality care and improves health care access and outcomes [15].

The prevalence of diabetes was 9.2% (male: 8.8%, female: 9.6%) and prediabetes was 13.3% (male: 13%, female: 13.6%) in 2017. Among the patients, only 30.4% had controlled diabetes, 35.2% took treatment regularly and 61.5% were not aware of their diabetic condition. The factors related to getting diabetes were increasing age, overweight, and hypertension. The proportional mortality was 3% from diabetes of total death in all ages. In Bangladesh, 17% population was overweight (male: 14.4%, female: 19.6%), 3.3% were obese (male: 2%, female: 4.6%), and 25.1% had physical inactivity (male: 9.2%, female: 41.3%), those are the related risk factors for diabetes [16]. For the national response to diabetes, Bangladesh has an operational policy, strategy, and action plan for controlling diabetes and reducing physical inactivity, but not for reducing overweight and obesity. There are evidence-based national diabetes guidelines available, but not fully implemented. There are no set standard criteria for referral of patients from primary care to higher levels of care. In the primary care facilities, there are only blood glucose measurements and urine strips for glucose and ketone measurements generally available, but no facilities for insulin, metformin, sulphonylurea, oral glucose tolerance test, hemoglobin A_1c (HbA_1c) test, dilated fundus examination, retinal photocoagulation, foot vibration perception by tuning fork, renal replacement therapy by dialysis, foot vascular status by Doppler, renal replacement therapy by transplantation in 2016 [17].

As there are no standard criteria for referring patients from primary care to a higher level of care, we will facilitate the patients to acquire self-management skills to understand the risk factors for diabetic complications and seek treatment in referral hospitals as necessary. They can attend referral hospitals to prevent diabetic complications by doing HbA_1c tests, dilated fundus examinations, retinal photocoagulation, foot vibration perception by tuning fork, renal replacement therapy by dialysis and transplantation, and also foot vascular status by Doppler.

A pilot study with a quasi-experimental pre- and postintervention design will be implemented. As we will try to explore the participants’ characteristics, we want to conduct a pilot study to see the feasibility of this project among these participants. We plan to conduct quasi-experimental pre- and postintervention design, as we found in this setting randomization; case-control is rather difficult. Therefore, we will enroll the participants and collect baseline data and then we will educate them, and after 6 months we will evaluate them and compare the baseline (pretest) and the endline (posttest) data of individual participants. We set 6 months, as a previous study showed that a patient’s behavioral modification requires at least 6 months of intervention [18]. The study duration will be 1 year after getting approval from the Ethical Committee.

The participants are people with diabetes, who take services from Grameen primary health centers (PHCs). We use 2 PHCs from Sahorail and Jamshahat of Manikganj District in Bangladesh.

We will use a purposive sampling technique to select the participants. Patients who meet the eligibility criteria will be introduced by physicians at the PHCs, and the nurses will contact them at the PHC and obtain their consent.

We calculated the sample size using G*Power software (version 3.1.9.7; Heinrich-Heine-University). As this is a pilot study, we set an effect size of 0.39 considering the differences between 2 dependent matched pair means of HbA_1c from a previous study [19], with a level of significance of 5%, and 80% power, the total sample size is calculated at 54. As patients have many options to discontinue the study (consent, withdraw, migration, change the health care facilities based on the disease severity, complications, hospitalization, etc), we consider a 30% dropout (16 participants) for this study. Therefore, the total sample size is estimated to be 70 (Textbox 1).

The principal investigator (PI) and co-investigators (telenurses) received training in telenursing such as communication and behavior modification techniques, and self-management skills on diabetes including blood sugar control and foot care. They will receive study-specific training from other coinvestigators and one diabetic consultant on data collection such as how to collect data and what type of tool has to be used during data collection. The patients who will attend the PHCs and telenurses will identify the patients with diabetes by checking the patient’s blood test report. They will check the participants’ eligibility criteria (inclusion and exclusion criteria) and obtain written informed consent. It will be ensured that there will be no risk in disclosing the information.

They will educate patients using an investigator-developed “Education Booklet” at the PHCs. The booklet will be given to the patients after receiving consent and health education will be provided at the time as scheduled (Multimedia Appendices 1 and 2). The data will be collected within a 6-month study period using:

All of the above except Diabetes management self-efficacy scale (number 3), was reviewed by the investigator team with the telenursing, diabetes, and chronic care nursing specialists for validity.

Data on all complications of diabetes will be asked of the patients by the investigators and check the accuracy of the information from the records.

We will use the telenursing model with the collaboration of the Hiroshima University telenursing center and the Nursing Research Center of Grameen Caledonian College of Nursing (GCCN) (Figure 1).

Since this is a pilot study, we set various indicators (Multimedia Appendix 5). The primary outcome is set as a change in HbA_1c. As the secondary outcomes, we set various evaluation indicators. The data collection schedule is also set in Multimedia Appendix 5.

Sociodemographic data, clinical history, and lifestyle are taken at the initial assessment (Initial assessment sheet). Satisfaction is measured by the Likert scale (Satisfaction scale). Achievement of monthly goals is measured by percentage. Behavior change is measured by the researcher-developed scale (Lifestyle behavior questionnaire). Self-efficacy is measured by the Diabetes Management Self-Efficacy Scale.

Qualitative data will be interviewed, described, or recorded when it occurs. Engagement and follow-up rate, education material used, complication management, and “patients who have achieved HbA_1c in recommended level” will be counted. Cost-effectiveness will be calculated.

Descriptive statistics will be expressed as frequencies and percentages for categorical variables and mean with SD or median with quantile, distribution, and range for the continuous variables. To compare the categorical variables between pre- and postdata, the chi-square test will be performed. To compare feasibility and efficacy (pre and post), continuous variables will be compared by paired t test or one-way ANOVA for the normally distributed and or McNemar test or Wilcoxon signed-rank sum test for the not normally distributed variables after checking the data normality. Qualitative data will be described and categorized if necessary. Statistical significance will be set as <0.05. Data will be analyzed using IBM SPSS Statistics for Windows, Version 25.0 (IBM Corp).

This study was approved by the institutional review board of the Bangladesh Medical Research Council (BMRC/NREC/2022-2025/336). The researcher will explain the consent procedures including the purpose, procedure, confidentiality, right to withdraw from the study, risk, and benefits, and will obtain written informed consent (ICFs) individually from all the participants. To maintain privacy and confidentiality, data will be collected anonymously. The data will be stored on two password-protected computer sets in the GCCN research room. After deleting all personal identifying information, anonymized data will be used for data analysis, so that research participants will not be identified. To participate in this study, we will not provide any money to the participants. We will provide all the treatments free of cost. As there is no risk or minimum risk to participate in this study, therefore, we will not provide any compassion to participate in this study. We ensure that identifiable features of research participants in any images of the manuscript or supplementary material will not be visible.

The results of the research will be disseminated in international scientific conferences and will be published in the International Science Citation Index (SCI) Journals. If the results show significance, we will share them with the policymakers, stakeholders, and the research community to implement such interventions in the government and private hospitals. Patients with diabetes will benefit, and it will reduce morbidity and mortality and will reduce patients’ and national economic burden. To control diabetes, health education and lifestyle changes such as food habits, exercise, and medication adherence are imperative. By doing this research, we can improve quality of life by controlling diabetes and preventing complications and death. In this way, we can also decrease the number of hospital visits and admissions and economic burden. This study will increase patients’ health literacy so that they can share their health knowledge with their peers and in the community. The study findings may assist us in the future implementation of telenursing interventions with a large sample size for determining factors that influence the quality of life among patients with diabetes.

By implementing this pilot study, we would like to see the feasibility and significance of this study. We can understand the potential barriers to use the telenursing system. Based on this study, we can revise the methodology and use multiple sites to make further research more effective. If we find our disease management program is effective, we can scale up this program throughout the country. Moreover, government and other nongovernment and private organizations can adopt this program and integrate into the existing health care system of Bangladesh. We can establish a public-private partnership incorporating all the stakeholders to develop a sustainable telenursing system [21].

This study has certain limitations. As we use a purposive sampling technique for selecting the study sites and participants, it causes selection bias. This is a pre- and poststudy design, not using any control group, and thus no causal inferences could be made. We will use appropriate statistics to understand associations in outcome measures to minimize biases [22]. We use 2 rural PHCs from one district; therefore, our findings cannot be generalized for the population of the whole country. Some of the enrolled patients may not understand and follow the study procedures, so we can arrange group education via video conference to minimize this.

GCCN has 76 different PHCs throughout Bangladesh. PHC receives patients with diabetes. They also have laboratory facilities to diagnose patients with diabetes. In this study, we have trained investigators and diabetic consultants who will conduct research activities and will provide consultancy. All the data will be entered into a password-protected computer and documents will be kept in the cabinet with a lock and key. Telecommunication will be conducted using smartphones.

By participating in this study, patients with diabetes will acquire disease-specific self-management skills and can manage a healthy lifestyle and prevent complication.